A clinical trial is a research study conducted with volunteers to evaluate the safety & effectiveness of a new medical treatment or intervention. It involves carefully designed protocols and methodology to gather scientific evidence and assess the potential benefits and risks of the intervention. These trials play a crucial role in advancing medical knowledge and improving healthcare by testing new drugs, therapies, and medical devices before they can be approved for widespread use.
MacTel is a bilateral retinal disease that leads to a gradual loss of central vision. The disease causes photoreceptors to be lost in a well-defined area (Ellipsoid Zone) of the retina. As the disease progresses, patients experience blurring, distorted vision, trouble reading, and loss of central vision. Our Encapsulated Cell Therapy (ECT) Platform releases Ciliary Neurotrophic Factor (CNTF), a protein shown to protect against the progressive loss of photoreceptors.
There are no known pharmacological treatment options for MacTel today.
Neurotech required conditions for consideration of Pre-Approval Access and Single Patient Requests
Glaucoma is a disease of the optic nerve, characterized by the selective loss of retinal ganglion cells and associated reduction in the visual field. When the nerve is damaged, visual information loses the medium by which it is transferred to the brain. Over time, vision is slowly lost. All currently approved glaucoma medications are directed toward lowering intraocular pressure. However, another potential approach is protection against retinal ganglion cell atrophy. The protective effect of CNTF on retinal ganglion cells in laser-induced ocular hypertensive models has been previously demonstrated. Neurotech Pharmaceuticals is investigating the CNTF-producing NT-501 device for treatment of glaucoma.